Drug Database
DI

diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine (KD370 / KD 370 / Quintovac)

✓ Approved

Meiji Holdings · Vaccine · Vaccine

What is diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine?

diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine is a vaccine developed by Meiji Holdings. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesKD370, KD 370, Quintovac
CompanyMeiji Holdings
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Meiji Holdings

Therapeutic Indications

diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine is developed for 4 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved
Surgical and medical proceduresPolio immunisation✓ Approved

Related Research Articles

PubMedFrontiers in public health2026-10-15

Analysis of 92 hospitalized cases of non-neonatal tetanus in Guizhou Province, China.

Li Jiao J, Zhang Dandan D, Zhang Ruizhi R, Zhang Leibing L et al.

Tetanus has a high mortality rate and remains a major public health threat in low- and middle-income countries. Although neonatal tetanus has been eliminated in China, the burden of non-neonatal tetanus is still heavy. This study analyzed the case characteristics, outcomes, and hospitalization expenses of non-neonatal tetanus inpatients in Guizhou Province, China, and provided a basis for reducing the disease burden. One tertiary medical institution was randomly selected from each of the nine cities (states) in the province, and the data of non-neonatal tetanus hospitalized cases from 2021 to 2025 were collected. Descriptive epidemiological methods, the simple seasonal index method, and multiple linear regression were used in the analysis. A total of 92 cases were included. Males accounted for 65.22% (60/92); farmers accounted for 86.96% (80/92); the median age was 60 (55-69) years; the incubation period ranged from 1 to 27 days; and cases peaked in summer. 95.65% (88/92) were not vaccinated with tetanus toxoid-containing vaccine (TTCV), and only 21.74% (20/92) received standardized treatment within 24 h after injury. The case fatality rate was 15.22% (14/92). None of the non-survivors were inoculated with TTCV, no standardized treatment was performed within 24 h after injury, the severity was severe or above, and the family members gave up treatment on their own. The median hospitalization cost was 55,724 yuan (equivalent to 8,359 US Dollars); the highest was 239,365 yuan (equivalent to 35,905 US Dollars); and the number of hospitalization days was the main influencing factor (t = 5.751, p < 0.001). Non-neonatal tetanus in Guizhou Province was mainly in middle-aged and older male farmers, with a high incidence in summer, and most of them were not vaccinated with TTCV. The non-survivors were not vaccinated with TTCV and did not receive standard treatment within 24 h after injury. The disease had a high case fatality rate and was a serious economic burden. It is recommended to strengthen TTCV vaccination and standardized post-exposure disposal in high-risk groups, enhance medical financial support to prevent abandonment of treatment for economic reasons, and ensure that patients receive timely and comprehensive clinical care.

PMID 42876694
Read full article →
PubMedBMJ public health2026-10-15

Infant vaccination coverage trajectories and immunisation system archetypes in the WHO African region, 2019-2024: a longitudinal analysis of 47 countries.

Adamu Abdu A AA, Teka Bekele Aschalew A, Masresha Balcha Girma BG, Rey Lynda L et al.

COVID-19 disrupted childhood vaccination, but country-specific heterogeneity in diphtheria-tetanus-pertussis-containing vaccines (DTP3) coverage across the WHO African region remains poorly understood. This study addressed this gap by quantifying temporal trajectories and identifying latent structural patterns in DTP3 coverage across all 47 countries in the WHO African region from 2019 to 2024, spanning the onset and recovery phases of the COVID-19 pandemic. Country-level DTP3 coverage data from 2019 to 2024 were extracted from the WHO/United Nations Children's Fund Estimates of National Immunisation Coverage, published in July 2025. Country-specific ordinary least squares regression models estimated annual rates of change (slopes) in DTP3 coverage, while linear mixed-effects modelling decomposed within-country and between-country variance components. Principal component (PC) analysis (PCA) was then applied to the 6-year coverage matrix to derive two dominant, uncorrelated components capturing coverage level (PC1) and temporal trajectory (PC2). K-means clustering of PC scores grouped countries into empirically distinct immunisation system archetypes. Between 2019 and 2024, the estimated annual rate of change in DTP3 coverage was positive in 21 countries and negative in 24; Eritrea and Burkina Faso showed no evidence of a linear trend. The fixed-effect slope was 0.07 percentage points per year (95% CI -0.34 to 0.47; p=0.75), indicating no statistically significant net regional change, while between-country heterogeneity was substantial (random-intercept variance, 188.18; random-slope variance, 1.18). PCA showed that PC1 dominated, explaining 93% of variance (capturing sustained coverage level), with PC2 contributing an additional 3% (capturing temporal trajectory). K-means clustering of PC scores yielded four archetypes: cluster 1 (high coverage, consolidating; n=15), cluster 2 (chronically low coverage, divergent trajectories; n=9), cluster 3 (mid-low coverage, predominantly improving; n=11) and cluster 4 (mid-high coverage, erosion risk; n=12). This study generated an empirically derived, model-driven typology of immunisation system performance across the WHO African region, characterised by four distinct DTP3 coverage archetypes. The typology provides decision-makers with a granular basis for differentiating programmatic strategies, prioritising resource deployment and designing cluster-specific implementation research rather than applying uniform regional solutions.

PMID 42876748
Read full article →
PubMedFrontiers in cellular and infection microbiology2026-10-15

Immunogenicity and protective efficacy of recombinant BCG expressing a multi-epitope vaccine against mycobacterium tuberculosis.

Zhang Xuan-Ji XJ, Luo Jia-Rui JR, Tian Ting-Ting TT, Shi Juan J et al.

Mycobacterium tuberculosis (Mtb) infects approximately one-quarter of the global population, of whom 5%-10% develop active tuberculosis (TB). Although Bacillus Calmette-Guérin (BCG) remains the cornerstone vaccine against severe infant TB, its efficacy in adults is limited, underscoring the need for novel TB vaccines. This study aimed to design a multi-epitope vaccine, tMEV, and validate its protective potential through bioinformatic prediction and in vivo experiments. tMEV was constructed from dominant T- and B-cell epitopes derived from Mtb ESAT-6, PE35, PPE38, and PE4 proteins, fused with an adjuvant. Its vaccine candidacy was assessed via physicochemical and solubility profiling, secondary and tertiary structure modeling, TLR-4 molecular docking, molecular dynamics simulation, and immune simulation. The tMEV coding sequence was cloned into pMV361 and transformed into BCG to generate recombinant BCG (rBCG-tMEV). Immunogenicity, antigenicity, and protective efficacy were evaluated in mouse immunization and Mtb challenge models. tMEV exhibited favorable vaccine-like properties in silico. In mice, both tMEV and rBCG-tMEV induced Mtb-specific immune responses. Compared with PBS, tMEV significantly enhanced cellular and humoral immunity with a Th2-biased profile. Relative to conventional BCG, rBCG-tMEV elicited a superior mixed Th1-Th2 response and higher antigen-specific immunity, accompanied by increased secretion of IFN-γ, IL-2, TNF-α, granzyme B, and perforin. Moreover, rBCG-tMEV markedly reduced bacterial loads in the lungs and spleens of Mtb-infected mice, conferring partial protection. These findings demonstrate that tMEV and rBCG-tMEV possess robust immunogenicity and protective potential against Mtb, representing promising novel TB vaccine candidates and providing a rationale for future vaccine development and optimization.

PMID 42876677
Read full article →
PubMedInfectious diseases and therapy2026-10-15

A Phase 2 Trial Evaluating the Immunogenicity and Safety of an mRNA-Based Seasonal Influenza Vaccine Candidate Encoding Hemagglutinin and Neuraminidase.

Moldt Brian B, Ubeda Rafael A RA, Murray Alexander V AV, Tima Giresse G et al.

Influenza vaccines targeting both hemagglutinin (HA) and neuraminidase (NA) might offer broader protection than current vaccines, which primarily target HA. This randomized phase 2 study evaluated the immunogenicity and safety of an investigational mRNA-based trivalent seasonal influenza vaccine encoding HA and NA from A/H1N1, A/H3N2, and B/Victoria (FLUm3HA-3NA). Participants aged 18-64 years (younger adults) or 65-85 years (older adults) received one of several mRNA vaccine formulations-each containing different influenza A and B HA mRNA doses-or an age-appropriate licensed seasonal influenza vaccine as a comparator. Four formulations per age cohort were tested in part 1 of the study, and one formulation per age cohort in part 2. Day-29 hemagglutination inhibition (HI) and NA inhibition (NI) responses were assessed as primary and secondary endpoints, respectively, safety/reactogenicity as the secondary, and virus neutralization as the tertiary endpoint. A total of 250 younger and 260 older adults were vaccinated in part 1; 161 and 162, respectively, in part 2. All FLUm3HA-3NA formulations induced HI, NI, and neutralizing responses above baseline. In part 1, HI responses against A/H1N1 and A/H3N2 were similar or higher after FLUm3HA-3NA than after comparator vaccination in both age groups. For B/Victoria, HI responses were lower or similar versus comparator vaccination in younger adults and similar or higher in older adults. In part 2, HI responses were similar or higher with FLUm3HA-3NA versus comparators for A/H1N1 and A/H3N2, and lower for B/Victoria in both age groups. In both study parts and both age groups, NI titers were higher for all three strains with FLUm3HA-3NA versus comparators, and neutralizing titers were similar or higher for A/H1N1 and A/H3N2 and similar for B/Victoria. No safety concerns were identified. FLUm3HA-3NA induced HI, NI, and neutralizing responses, with an acceptable safety profile. The results support further development, including optimization of the influenza B HI response. ClinicalTrials.gov: NCT06431607.

PMID 42875682
Read full article →
PubMedInfectious diseases and therapy2026-10-15

A Phase 1/2 Trial Evaluating the Safety and Immunogenicity of an mRNA-based Seasonal Influenza Vaccine Candidate Encoding Hemagglutinin and Neuraminidase.

De Coster Ilse I, Cardona Jose F JF, Ferguson Murdo M, Leroux-Roels Isabel I et al.

Hemagglutinin (HA) is the principal immunologic target of most licensed seasonal influenza vaccines. Targeting both HA and neuraminidase (NA) might improve vaccine effectiveness. This randomized phase 1/2 study evaluated an investigational mRNA-based quadrivalent seasonal influenza vaccine, encoding HA and NA of A/H1N1, A/H3N2, B/Victoria, and B/Yamagata (FLUm4HA-4NA). In phase 1, adults aged 18-50 years received either one of twelve mRNA vaccine formulations of varying HA-only or HA and NA mRNA doses, or a licensed quadrivalent seasonal influenza comparator. In phase 2, participants aged 18-64 years (younger adults) and 65-85 years (older adults) received FLUm4HA-4NA (three groups per age category, with different HA/NA mRNA doses) or age-appropriate licensed quadrivalent comparator. Primary endpoints were safety/reactogenicity, and hemagglutination inhibition [HI] and NA inhibition [NI] responses against the four seasonal strains at day 29. Cross-reactive HI/NI responses against drifted strains, virus neutralization, and HA-/NA-specific cell-mediated immunity were evaluated in phase 2 as tertiary objectives. A total of 293 participants (21-25 per group) were vaccinated in phase 1, 480 younger (108-137 per group) and 483 older adults (117-125 per group) in phase 2. Solicited events were more frequent with FLUm4HA-4NA than comparators and were mostly short-lived and mild or moderate. No deaths or vaccine-related serious adverse events were reported. Post-vaccination HI and neutralizing titers in the FLUm4HA-4NA groups were similar or higher for the A strains and lower for the B strains versus comparators. NI responses exceeded those of comparators for all four strains. HI and NI titers against evaluated drifted A strains were similar or higher after FLUm4HA-4NA than after comparator vaccination. HA-specific CD4+ and CD8+ T-cell responses were generally higher after FLUm4HA-4NA than comparator vaccination. FLUm4HA-4NA showed an acceptable safety profile and humoral and cellular immunogenicity in the study population, supporting further development and formulation optimization to improve influenza B HI responses. ClinicalTrials.gov: NCT05823974; euclinicaltrials.eu: 2022-502308-66-00.

PMID 42875683
Read full article →
PubMedNature medicine2026-10-15

Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.

Sellars MacLean C MC, Frank Jessica A JA, Shim Bohoon B, Vanasse Allison A et al.

Personalized neoantigen-targeting cancer vaccines in the adjuvant setting are of increasing interest across malignancies. Here we report the results of a phase 1 clinical trial testing the feasibility and safety of personalized neoantigen-targeting cancer vaccines for high-grade epithelial ovarian cancer. 'NeoVax' consisted of pools of synthetic long peptides targeting patient-specific neoantigens admixed with the immunostimulant poly-ICLC, was combined with delayed administration of anti-PD-1 antibody, and was tested in ten patients (one newly diagnosed patient (Cohort A) and nine patients at first recurrence (Cohort B)) with platinum-sensitive ovarian cancer following standard-of-care platinum doublet chemotherapy. Nine of 12 evaluable Cohort B patients were vaccinated (75%, 90% CI 47-93%) and 1 of 9 Cohort A patients (11%, 90% CI 0.6-43%). No unexpected safety signals were encountered and no patients discontinued treatment due to toxicity. Across patients, >70% selected targets remained detectable by noninvasive cell-free DNA analysis despite a median of 6.5 months from the time of diagnostic biopsy to vaccine administration, during which, patients received standard-of-care chemotherapy. Biomarker analysis was suggestive of biologic activity of the vaccine in six of ten patients and this was associated with broader tumor and vaccine-specific immune responses in blood and tumor following vaccination. Resistant tumor clones reflected diverse mechanisms affecting antigen presentation, indicative of immune-selective pressure exerted by vaccination. Overall, the interplay between the repertoire of antigens presented by the tumor and the breadth of induced immunity seemed to dictate clinical efficacy following vaccination. ClinicalTrials.gov identifier: NCT04024878 .

PMID 42875558
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine